97 related articles for article (PubMed ID: 17255289)
1. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
Weitzel JN; Buys SS; Sherman WH; Daniels A; Ursin G; Daniels JR; MacDonald DJ; Blazer KR; Pike MC; Spicer DV
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):654-8. PubMed ID: 17255289
[TBL] [Abstract][Full Text] [Related]
2. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram IT; Ursin G; Spicer DV; Pike MC
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1117-20. PubMed ID: 11700258
[TBL] [Abstract][Full Text] [Related]
3. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
[TBL] [Abstract][Full Text] [Related]
4. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
[TBL] [Abstract][Full Text] [Related]
5. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.
Johansson H; Gandini S; Bonanni B; Mariette F; Guerrieri-Gonzaga A; Serrano D; Cassano E; Ramazzotto F; Baglietto L; Sandri MT; Decensi A
Breast Cancer Res Treat; 2008 Mar; 108(1):57-67. PubMed ID: 17468953
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
Akira S; Mine K; Kuwabara Y; Takeshita T
Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
[TBL] [Abstract][Full Text] [Related]
7. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
8. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
Stuedal A; Ma H; Bjørndal H; Ursin G
Climacteric; 2009 Jun; 12(3):248-58. PubMed ID: 19387884
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
[TBL] [Abstract][Full Text] [Related]
11. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
[TBL] [Abstract][Full Text] [Related]
13. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer.
Khan QJ; Kimler BF; O'Dea AP; Zalles CM; Sharma P; Fabian CJ
Breast Cancer Res; 2007; 9(3):R35. PubMed ID: 17537236
[TBL] [Abstract][Full Text] [Related]
14. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey ES
Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
[TBL] [Abstract][Full Text] [Related]
16. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
Lethaby AE; Vollenhoven BJ
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
[TBL] [Abstract][Full Text] [Related]
17. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density.
Hofling M; Lundström E; Azavedo E; Svane G; Hirschberg AL; von Schoultz B
Climacteric; 2007 Apr; 10(2):155-63. PubMed ID: 17453864
[TBL] [Abstract][Full Text] [Related]
18. Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.
Lundström E; Söderqvist G; Svane G; Azavedo E; Olovsson M; Skoog L; von Schoultz E; von Schoultz B
Fertil Steril; 2006 Apr; 85(4):989-95. PubMed ID: 16580385
[TBL] [Abstract][Full Text] [Related]
19. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
20. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density.
Lundström E; Bygdeson M; Svane G; Azavedo E; von Schoultz B
Climacteric; 2007 Jun; 10(3):249-56. PubMed ID: 17487652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
